Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Equity Ratio (2018 - 2025)

Historic Equity Ratio for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 0.89.

  • BioNexus Gene Lab's Equity Ratio rose 474.6% to 0.89 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.89, marking a year-over-year increase of 474.6%. This contributed to the annual value of 0.8 for FY2024, which is 584.54% down from last year.
  • BioNexus Gene Lab's Equity Ratio amounted to 0.89 in Q3 2025, which was up 474.6% from 0.8 recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Equity Ratio high stood at 0.89 for Q3 2025, and its period low was 0.69 during Q1 2021.
  • In the last 5 years, BioNexus Gene Lab's Equity Ratio had a median value of 0.8 in 2025 and averaged 0.8.
  • In the last 5 years, BioNexus Gene Lab's Equity Ratio plummeted by 8905.08% in 2021 and then skyrocketed by 1406.97% in 2022.
  • BioNexus Gene Lab's Equity Ratio (Quarter) stood at 0.75 in 2021, then increased by 1.69% to 0.76 in 2022, then rose by 11.1% to 0.85 in 2023, then fell by 5.85% to 0.8 in 2024, then increased by 12.12% to 0.89 in 2025.
  • Its Equity Ratio was 0.89 in Q3 2025, compared to 0.8 in Q2 2025 and 0.82 in Q1 2025.